Alopecia Areata Treatment A Daily Pill Regrew Hair for About Half of Patients

Alopecia areata is not ordinary hair shedding. It is an autoimmune condition in which the immune system attacks hair follicles, causing patches of hair loss that can spread to the whole scalp, the eyebrows and the eyelashes. Two large trials published in JAMA Dermatology in August 2026 add a new option to alopecia areata treatment: a once-daily pill called upadacitinib.

What is alopecia areata?

In alopecia areata, immune cells target hair follicles, which stop producing hair without being destroyed — which is why regrowth is possible. It can affect anyone, at any age, and beyond the physical change it often takes a heavy emotional toll.

The new treatment: upadacitinib

Upadacitinib belongs to the JAK inhibitor family, drugs that calm specific immune signals. It is already used for conditions such as rheumatoid arthritis and eczema.

How the trials worked

• 1,399 people aged 12 to 64 took part, including 118 adolescents; 59% were women.
• All had severe alopecia areata, with at least half the scalp affected — on average, about 84% of scalp hair was missing at the start.
• Participants were randomly given 15 mg, 30 mg or a placebo every day for 24 weeks, followed by a 28-week extension.

Results: how much hair grew back?

Scalp hair

The main goal was reaching 80% or more scalp coverage. Across the two trials, about 45% of people on 15 mg and about 54–55% on 30 mg reached it. Some went further: around 14% (15 mg) and 20–22% (30 mg) had complete scalp regrowth.

Eyebrows and eyelashes

Roughly 40% of people on 15 mg and close to 60% on 30 mg saw meaningful improvement in their eyebrows and eyelashes, versus a few percent on placebo. Quality-of-life scores improved as well.

Side effects of upadacitinib

No new safety concerns were found compared with what is already known about the drug. Serious side effects were uncommon — about 2% on the active doses versus 0.4% on placebo.

The most common side effects

• Acne, in about 12% (15 mg) and 16% (30 mg) of participants — worth knowing if you are acne-prone.
• Colds and upper respiratory infections, similar to or slightly more frequent than on placebo.
• Raised muscle enzyme (CPK) levels in blood tests.

JAK inhibitors as a family carry warnings about serious infections, blood clots, heart events and certain cancers, which is why they require medical follow-up and regular blood tests.

The limits of the trials

• Durability: the main comparison covered 24 weeks. What happens over years, or after stopping treatment, still needs answers.
• Funding: the trials were sponsored by the drug’s maker, AbbVie, and several authors work for the company — standard for drug trials, but worth knowing.
• Teenagers: only 118 adolescents took part, so evidence for younger patients is more limited.

What it means for alopecia areata treatment

Upadacitinib joins other JAK inhibitors, such as baricitinib and ritlecitinib, that have already changed the outlook for severe alopecia areata. Whether it is approved and reimbursed for this use depends on where you live. If you have patchy or extensive hair loss, start with a dermatologist: alopecia areata needs a proper diagnosis, because other types of hair loss — hormonal, nutritional or stress-related — are treated very differently.